Johnson & Johnson Ranks 50th in Market Activity with $1.102 Billion Trading Volume

On March 27, 2025, Johnson & Johnson (JNJ) saw a trading volume of $1.102 billion, ranking 50th in the day's market activity. The stock rose by 0.87%, marking its second consecutive day of gains, with a total increase of 1.31% over the past two days.

Johnson & Johnson MedTech is set to showcase its latest advancements in heart disease treatment with the Impella heart pump at the ACC.25 conference. The Impella device has been upgraded to Class 2a in the ACC/AHA treatment guideline for cardiogenic shock secondary to STEMI, highlighting its significance in the medical field.

Johnson & Johnson has announced a significant investment of over $55 billion in the U.S. over the next four years. This investment includes the construction of four new manufacturing facilities, with the groundbreaking of a $2 billion+ facility in North Carolina. The company aims to support American jobs and enhance its portfolio of transformational medicines, with an estimated economic impact of over $100 billion per year.

Johnson & Johnson MedTech has launched the DUALTO™ Energy System, designed to offer a simplified user experience and flexible application across various surgical treatment approaches. The system has received 510(k) clearance from the U.S. Food & Drug Administration and will be showcased at the Association of periOperative Registered Nurses Global Surgical Conference & Expo in April 2025.

Johnson & Johnson MedTech has received clearance for the MONARCH™ QUEST, an enhanced robotic-assisted bronchoscopy system powered by next-generation NVIDIA AI navigation software. This advancement elevates the MONARCH™ Platform, providing more precise and efficient procedures for patients.